#1 Clinical Trials Search in Europe

Meropenem

Meropenem is a powerful antibiotic used to treat various serious bacterial infections. This article explores recent clinical trials investigating the use of meropenem in different patient populations and conditions. We’ll look at studies examining its pharmacokinetics, safety, and effectiveness when administered through different methods and in combination with other drugs. Understanding these trials can provide valuable insights into optimizing meropenem treatment for better patient outcomes.

Table of Contents

What is Meropenem?

Meropenem is a powerful antibiotic medication that belongs to a class of drugs called carbapenems. It’s also known by the brand names Merrem® or Meronem®[7][8]. This antibiotic is used to treat a wide range of serious bacterial infections, particularly those that are resistant to other antibiotics[1].

Uses of Meropenem

Meropenem is prescribed for various severe infections, including:

  • Sepsis and Septic Shock: These are life-threatening conditions caused by the body’s response to infection[2].
  • Pneumonia: Including ventilator-associated pneumonia in critically ill patients[3].
  • Meningitis: An infection of the protective membranes covering the brain and spinal cord[7].
  • Central Nervous System (CNS) Infections: Particularly after neurosurgery[4].
  • Pulmonary Exacerbations in Cystic Fibrosis: Used to treat lung infections in patients with this genetic disorder[8].
  • Complicated Intra-abdominal Infections: Such as severe cases of appendicitis or peritonitis[5].

How Meropenem Works

Meropenem is a broad-spectrum antibiotic, which means it can fight many different types of bacteria. It works by interfering with the bacteria’s ability to form cell walls, which are crucial for their survival. Without proper cell walls, the bacteria die, helping to clear the infection[1].

One of the key advantages of meropenem is its effectiveness against bacteria that have become resistant to other antibiotics. This makes it particularly valuable for treating serious infections in hospital settings where antibiotic resistance is a growing concern[6].

Administration and Dosage

Meropenem is typically administered intravenously (through a vein) in a hospital setting. The dosage and duration of treatment can vary depending on several factors, including:

  • The type and severity of the infection
  • The patient’s age and weight
  • The patient’s kidney function

Some common dosing regimens include:

  • For adults: 1-2 grams every 8 hours[1]
  • For children with meningitis: 40 mg/kg every 8 hours (or every 12 hours for very young infants)[7]
  • For patients with cystic fibrosis: 40 mg/kg every 8 hours, given as a 3-hour infusion[8]

In some cases, meropenem may be given as an extended or continuous infusion to maintain effective levels of the antibiotic in the body[1].

Effectiveness and Safety

Meropenem has been shown to be effective in treating a wide range of serious bacterial infections. Its broad-spectrum activity makes it a valuable tool in fighting complex infections, especially when the causative bacteria are unknown or resistant to other antibiotics[2].

Like all medications, meropenem can cause side effects. Common side effects may include:

  • Diarrhea
  • Nausea or vomiting
  • Headache
  • Skin rash
  • Pain or inflammation at the injection site

Serious side effects are rare but can include severe allergic reactions, seizures, or liver problems. It’s important to report any unusual symptoms to your healthcare provider immediately[7].

Special Considerations

Antibiotic Resistance: To prevent the development of antibiotic-resistant bacteria, meropenem should only be used when necessary and as prescribed by a healthcare professional[6].

Penetration into Cerebrospinal Fluid: Studies have shown that meropenem can penetrate the blood-brain barrier, making it effective for treating central nervous system infections[4].

Use in Cystic Fibrosis: Meropenem has been studied for its effectiveness in treating lung infections in patients with cystic fibrosis, showing promising results when administered as a prolonged infusion[8].

Combination Therapy: In some cases, meropenem may be used in combination with other antibiotics to enhance its effectiveness or to cover a broader range of potential pathogens[2].

Aspect Details
Patient Populations Adults with ventilator-associated pneumonia, infants with meningitis or intra-abdominal infections, patients with cystic fibrosis, critically ill patients
Administration Methods Bolus injection, continuous infusion, prolonged infusion (3 hours)
Dosages Studied Varying from 20 mg/kg to 40 mg/kg in infants, 1g to 2g in adults, adjusted based on renal function
Key Outcomes Measured Pharmacokinetics, safety profile, efficacy against infections, mortality rates, emergence of antibiotic-resistant bacteria
Special Considerations Blood-brain barrier penetration, impact of plasma exchange on drug levels, dosing adjustments for premature infants
Combination Therapies Meropenem alone vs. meropenem + moxifloxacin for severe sepsis/septic shock

FAQ

  • What is meropenem used for? Meropenem is a broad-spectrum antibiotic used to treat serious bacterial infections, including ventilator-associated pneumonia, intra-abdominal infections, meningitis, and sepsis. It's particularly effective against many gram-negative and gram-positive bacteria.
  • How is meropenem typically administered? Meropenem is usually given intravenously (through a vein). The dosage and administration method can vary depending on the patient's age, weight, kidney function, and the type of infection being treated. Some studies are exploring continuous infusion versus intermittent bolus administration.
  • Are there any special considerations for using meropenem in infants? Yes, several studies are investigating the appropriate dosing and safety of meropenem in infants, including premature babies. The correct dose for young infants is still being determined, as their bodies process drugs differently than older children or adults.
  • Can meropenem be used to treat meningitis? Yes, meropenem is being studied for use in bacterial meningitis, including in infants. Its ability to penetrate the blood-brain barrier is an important factor in its effectiveness against central nervous system infections.
  • What are some potential side effects of meropenem? While meropenem is generally well-tolerated, potential side effects can include diarrhea, nausea, headache, and skin rashes. In rare cases, it may cause seizures. Clinical trials are closely monitoring these and other potential adverse effects, especially in vulnerable populations like infants and critically ill patients.

Ongoing Clinical Trials on Meropenem

  • Study on the Safety and Absorption of Meropenem and Vaborbactam in Children with Complicated Urinary Tract Infections

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Italy Poland Spain

  • Study on Optimizing Initial Dosing of Flucloxacillin and Drug Combination for Critically Ill Patients with Sepsis in the ICU

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Effectiveness of Moxifloxacin and Drug Combination for Treating Bone Implant Infections in Patients with Long Bone Fractures

    Recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Study on the Effectiveness and Safety of 7 vs. 14 Days of Antibiotic Treatment with Meropenem for Patients with Pseudomonas Aeruginosa Blood Infection

    Recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Study on Early Oral Antibiotic Treatment for Vertebral Osteomyelitis Using Cefuroxime, Dicloxacillin, and Ceftriaxone for Adult Patients

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Early Stopping of Antibiotic Treatment in Children with Cancer and Febrile Neutropenia

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study comparing 3-week versus 6-week antibiotic treatment for patients with drained pyogenic liver abscess

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    France

  • Study of antibiotic treatment effectiveness in critically ill patients receiving drug combination therapy

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    France

  • Study on the Effectiveness and Safety of Extended vs. Intermittent Infusion of Meropenem in Critically Ill Children with Suspected or Proven Infection

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Hungary

  • Study Comparing Different Antibiotic Treatments for ICU Patients with Hospital-Acquired Sepsis: Focus on Cefepime and Drug Combination

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion. Understanding pharmacokinetics helps determine the appropriate dosing of a medication.
  • Ventilator-Associated Pneumonia (VAP): A type of lung infection that occurs in people who are on mechanical ventilation breathing machines in hospitals. It's a serious condition that can occur when bacteria enter the lungs through the breathing tube.
  • Sepsis: A life-threatening condition that occurs when the body's response to infection causes widespread inflammation, potentially leading to organ failure and death if not treated promptly.
  • Minimum Inhibitory Concentration (MIC): The lowest concentration of an antibiotic that prevents visible growth of a bacterium. It's used to determine the effectiveness of antibiotics against specific bacteria.
  • Blood-Brain Barrier (BBB): A protective barrier that separates the brain from the blood circulating around the body. It's crucial for drugs treating brain infections to be able to cross this barrier.
  • Continuous Infusion: A method of administering medication where the drug is given slowly and continuously over a period of time, often 24 hours, as opposed to intermittent bolus doses.
  • Therapeutic Plasma Exchange (TPE): A medical procedure used to treat various autoimmune disorders by removing and replacing a patient's plasma, which can affect how drugs like meropenem are processed in the body.
  • Cystic Fibrosis (CF): A genetic disorder that affects mostly the lungs, but also the pancreas, liver, kidneys, and intestine. People with CF are prone to serious lung infections that may require treatment with antibiotics like meropenem.

References

  1. https://clinicaltrials.gov/study/NCT02820987
  2. https://clinicaltrials.gov/study/NCT00534287
  3. https://clinicaltrials.gov/study/NCT02615041
  4. https://clinicaltrials.gov/study/NCT02506686
  5. https://clinicaltrials.gov/study/NCT02212392
  6. https://clinicaltrials.gov/study/NCT00410527
  7. https://clinicaltrials.gov/study/NCT01554124
  8. https://clinicaltrials.gov/study/NCT01429259